Earnings summaries and quarterly performance for Cosmos Health.
Executive leadership at Cosmos Health.
Board of directors at Cosmos Health.
Research analysts covering Cosmos Health.
Recent press releases and 8-K filings for COSM.
Cosmos Health Receives Analyst Coverage with $4.50 Valuation
COSM
Revenue Acceleration/Inflection
New Projects/Investments
M&A
- Zacks Small-Cap Research initiated coverage on Cosmos Health, assigning a $4.50 per share valuation based on a discounted cash flow analysis.
- The valuation is supported by projected revenue growth from approximately $64.4 million in 2025 to $98.6 million in 2026, and further to over $130 million by 2027.
- Key factors highlighted include a diversified revenue base, vertically integrated operations, technology-enabled initiatives, U.S. market expansion, and improving financial performance.
Jan 14, 2026, 4:25 PM
Cosmos Health Subsidiary Secures Manufacturing Deal for PathMuscle
COSM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Cosmos Health Inc.'s subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement with Libytec Pharmaceutical S.A. for the full end-to-end production of the pharmaceutical product PathMuscle.
- PathMuscle is an advanced generic pharmaceutical product indicated for the symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders.
- The agreement includes firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units.
- This collaboration is expected to enhance Cosmos Health's revenue visibility and support its strategic expansion in pharmaceutical manufacturing.
Jan 5, 2026, 2:30 PM
Cosmos Health Inc. Reports Record Q3 2025 Results
COSM
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Cosmos Health Inc. reported record Q3 2025 revenue of $17.11 million, a 38% increase from Q3 2024, and record gross profit of $2.60 million, up 116% year-over-year.
- The company achieved a record gross margin of 15.21% in Q3 2025, an improvement from 9.72% in Q3 2024, and Adjusted EBITDA improved 74% to ($0.19 million).
- Cash and cash equivalents significantly increased to $4.63 million as of September 30, 2025, from $0.66 million on June 30, 2025, contributing to a rise in total assets to $69.49 million.
- Cosmos Health secured a $300 million digital financing facility and commenced Ethereum purchases, strengthening long-term diversification and balance sheet resilience.
Nov 17, 2025, 9:30 PM
Cosmos Health Reports Record Q3 2025 Financial Results
COSM
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Cosmos Health Inc. achieved record revenue of $17.11 million in Q3 2025, marking a 38% increase from Q3 2024, and a record gross profit of $2.60 million, up 116% from the prior year.
- The company's gross margin expanded to a record 15.21% in Q3 2025, an improvement of 549 basis points compared to Q3 2024.
- Adjusted EBITDA (loss) improved 74% to ($0.19 million) in Q3 2025, from ($0.70 million) in Q3 2024.
- The cash and cash equivalents position significantly increased to $4.63 million as of September 30, 2025, up sharply from $0.66 million as of June 30, 2025.
- Cosmos Health secured a $300 million digital financing facility and commenced Ethereum purchases, strengthening its long-term diversification and balance sheet resilience.
Nov 17, 2025, 2:15 PM
Cosmos Health Regains Nasdaq Minimum Bid Price Compliance
COSM
Delisting/Listing Issues
- Cosmos Health Inc. (COSM) announced on October 16, 2025, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- This rule requires a minimum bid price of $1.00 per share.
- The company achieved compliance by maintaining a closing bid price at or above $1.00 per share for 18 consecutive business days, from September 22, 2025, to October 15, 2025.
- Nasdaq has closed the matter, resolving the previously disclosed non-compliance notice received on November 6, 2024.
Oct 17, 2025, 3:09 PM
Cosmos Health Regains Nasdaq Minimum Bid Price Compliance
COSM
Delisting/Listing Issues
- Cosmos Health Inc. received written notice on October 15, 2025, from Nasdaq, confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The company's common stock maintained a closing bid price at or above $1.00 per share for 18 consecutive business days, from September 22, 2025, to October 15, 2025.
- Nasdaq has closed the matter, indicating Cosmos Health is now in compliance with the minimum bid price requirement.
- CEO Greg Siokas stated that this compliance was achieved organically, reflecting the continued execution of strategic initiatives and strengthening fundamentals.
Oct 16, 2025, 12:15 PM
Cosmos Health Increases Ethereum Investment
COSM
New Projects/Investments
- Cosmos Health Inc. purchased an additional $500,000 worth of Ethereum (ETH) on October 10, 2025.
- This acquisition brings the company's total investment in Ethereum to $1.5 million.
- The purchase was executed pursuant to Cosmos Health's previously announced $300 million digital assets facility.
- This investment is part of the company's strategic initiative to diversify its balance sheet and leverage blockchain technology within the healthcare and digital wellness sectors.
- CEO Greg Siokas indicated that the company is seeing gains from earlier Ethereum investments and views digital assets as long-term investments and potential enablers of secure, decentralized healthcare solutions.
Oct 10, 2025, 12:03 PM
Cosmos Health Expands Sky Premium Life Nutraceuticals into Kuwait Market
COSM
New Projects/Investments
Product Launch
- Cosmos Health Inc.'s subsidiary, SkyPharm S.A., has entered into an exclusive distribution agreement with Diyar United for the marketing and sale of its Sky Premium Life® line of nutraceuticals in Kuwait.
- The agreement, dated September 28, 2025, includes an initial purchase order of over 65,000 units.
- This expansion targets Kuwait's nutritional supplements market, which was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030.
Oct 3, 2025, 7:57 PM
Cosmos Health Inc. Announces Annual Meeting Results and Increased Authorized Shares
COSM
Proxy Vote Outcomes
Board Change
Convertible Preferred Issuance
- Cosmos Health Inc. held its 2025 Annual Meeting of Stockholders on September 30, 2025, where all proposals passed.
- Stockholders approved an amendment to the Articles of Incorporation to increase the number of authorized shares of capital stock to 1,500,000,000 shares of Common Stock and 300,000,000 shares of "blank check" Preferred Stock. This amendment became effective on September 30, 2025.
- The company's stockholders elected six directors to serve until the next Annual Meeting: Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos.
Oct 1, 2025, 10:02 AM
Cosmos Health CEO Issues Letter Highlighting $300M Digital Financing Facility and 2024 Performance
COSM
Debt Issuance
New Projects/Investments
Earnings
- Cosmos Health secured a $300 million digital financing facility in August 2025, with 72.5% of net proceeds directed towards building a digital treasury reserve of assets like Ethereum and Bitcoin, and the balance allocated to working capital and growth initiatives. This facility provides capacity to invest over $200 million in digital assets.
- For the year ended December 31, 2024, Cosmos Health reported revenues of $54.43 million, an approximately 2% gain over 2023, and operating expenses decreased by approximately 24% year over year. However, the company recorded an adjusted EBITDA of ($3.73 million) and a net loss of ($4.74 million).
- The company expanded its manufacturing capabilities with the establishment of U.S.-based GMP-certified production in 2025 and completed Phase I upgrades at its Cana Laboratories in Greece in 2024, which is expected to generate more than $10 million in recurring annual gross profit at full capacity.
- In 2024, Cosmos Health acquired a 10-drug generics portfolio, diversifying its presence in the global generics market.
Sep 29, 2025, 1:59 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more